Novartis begins construction of new research centre in San Diego, US
The Swiss pharma company Novartis has begun work on a new global biomedical research centre in San Diego, United States. The 43,300 m2 facility will be operational in 2029 and house around 1,000 employees.
Select your language
Generated with artificial intelligence.
Listening:
Novartis begins construction of new research centre in San Diego, US
+Get the most important news from Switzerland in your inbox
The new centre is a key pillar of the pharmaceutical group’s planned $23 billion (CHF19 billion) investment in the US.
The facility is designed to accelerate the discovery of breakthrough drugs and will become an integral part of Novartis’s global research network, which includes sites in Basel, Switzerland, and Cambridge, Massachusetts, the company giant said.
+ Novartis announces billion-dollar investment in US
Researchers will focus on key therapeutic fields such as neuroscience, oncology, age-related diseases and regenerative medicine, exploiting state-of-the-art technology platforms.
“This new research centre will strengthen our scientific leadership and accelerate drug discovery for patients around the world,” said Fiona Marshall, president of Novartis’ biomedical research division, in a statement.
A key feature of the facility will be the advanced integration of artificial intelligence (AI) to ensure computational and data analysis capabilities at each stage of the discovery process.
More
US ‘strikes price cut deal’ with Swiss pharma giants
The investment has been welcomed by the local authorities. “This step by Novartis confirms San Diego as a place where revolutionary science comes to life and innovation translates into high-quality jobs and life-changing medicines,” said local mayor Todd Gloria in the press release.
+ Read how Trump upended the pharma industry
The new centre builds on more than 25 years of ties between Novartis and San Diego and is part of a broader expansion strategy in the US. This includes a new manufacturing unit in North Carolina, radioligand therapy manufacturing facilities in California, Florida and Texas, as well as the expansion of existing sites.
This development follows a period of strong pressure by the Trump administration on pharmaceutical companies to lower drug prices and manufacture locally.
Adapted from French by AI/sb
We select the most relevant news for an international audience and use automatic translation tools to translate them into English. A journalist then reviews the translation for clarity and accuracy before publication.
Providing you with automatically translated news gives us the time to write more in-depth articles. The news stories we select have been written and carefully fact-checked by an external editorial team from news agencies such as Bloomberg or Keystone.
If you have any questions about how we work, write to us at english@swissinfo.ch
External Content
In compliance with the JTI standards
More: SWI swissinfo.ch certified by the Journalism Trust Initiative
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.